Helix BioPharma Corp. will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, detailing its clinical development plans and corporate strategy. The company will highlight preparations for a Phase Ib/Randomized Phase II study of L-DOS47 combined with pembrolizumab for first-line non-small cell lung cancer treatment, alongside its planned uplisting to NASDAQ in Q1 2026. These milestones represent Helix's approach to accelerating oncology asset development and enhancing market visibility.
CEO Thomas Mehrling, MD, PhD, will deliver the presentation at 2:30 PM ET, accessible via the event webcast. Investors can also schedule one-on-one meetings with Mehrling for insights into the company's vision and growth strategy. The Investor Summit, organized by Investor Summit Group, focuses on connecting undervalued microcap companies with institutional investors and high-net-worth individuals.
Helix's pipeline centers on L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing tumors to improve therapy sensitivity. The compound has completed Phase Ib studies in NSCLC and underpins the company's next-generation bi-specific antibody-drug conjugates. Additionally, Helix is advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability comparable to IV administration for advanced cancers.
The presentation and planned NASDAQ uplisting underscore Helix's strategy to broaden its investor base and secure global capital access, supporting its mission to transform hard-to-treat cancers into manageable conditions. The company's progress in clinical development and corporate positioning will be closely watched by investors seeking exposure to innovative oncology therapeutics.
